Sai Life Sciences Limited
Bookbuilding IPO · NSE, BSE
- Price band
- ₹522 - ₹549
- Lot size
- 27 shares
- Issue amount
- ₹3,042.62 cr
- Total subscription
- 10.27×
- Opens
- 11 Dec 2024
- Closes
- 13 Dec 2024
- Allotment
- 16 Dec 2024
- Listing
- 18 Dec 2024
Offer at a glance
Issue overview
- Issue size
- 5,54,21,123 shares
- Face value
- ₹1 Per Share
- Minimum investment
- ₹14,094
- Fresh issue
- ₹950 cr
- Offer for sale
- ₹2,092.62 cr
- Registrar
- Kfin Technologies Limited
- Listing exchange
- NSE, BSE
- Maximum investment
- ₹14,823
- Issue type
- Bookbuilding IPO
- Shares before issue
- 19,06,85,340
- Shares after issue
- 20,79,89,529
Lot sizes
| Category | Lots | Shares | Amount |
|---|---|---|---|
| Retail | 1 | 27 | ₹14,823 |
| sHNI | 14 | 378 | ₹2,07,522 |
| bHNI | 68 | 1,836 | ₹10,07,964 |
Share reservation
Subscription & GMP
Subscription by category
Missing multiples are calculated from bids and offered shares when available.
GMP history
Application-wise demand
| Category | Reserved applications | Applied applications |
|---|---|---|
| RETAIL | 7,18,422 | 9,96,756 |
| HNIs(10L +) | 14,662 | 89,454 |
| HNIs (2-10L) | 7,331 | 20,392 |
Subscription demand
Amounts in ₹ crore. HNI subcategories are included in the NII total.
| Category | Offered | Demand |
|---|---|---|
| QIBs | 608.52 | 18,123.87 |
| RETAIL | 1,064.92 | 1,477.49 |
| HNIs 2+ | 152.13 | 423.19 |
| HNIs 10+ | 304.26 | 1,856.37 |
Financial performance
Company financials
In Crores · Reported periods may include interim results.
Key performance indicators
| Metric | Sep24 | Mar-24 | Mar-23 |
|---|---|---|---|
| EPS | 1.49 | 4.53 | 0.55 |
| ROE | 2.68 | 8.49 | 1.12 |
| ROCE | 3.9 | 10.26 | 5.13 |
| RONW | 2.68 | 8.5 | 1.13 |
| Pre IPO | 0 | 126.42 | 0 |
| Post IPO | 0 | 203.82 | 0 |
Values and labels as reported in the issue data.
Company information
Company profile
Sai Life Sciences Limited, incorporated in January 1999, specializes in researching, developing, and manufacturing small-molecule new chemical entities, serving over 280 innovator pharmaceutical companies in FY 2024, including more than 230 clients as of September 2024. Collaborating with 18 of the top 25 global pharmaceutical firms, the company provides services across the US, UK, Europe, and Japan, offering CMC/CDMO capabilities, integrated discovery through CRO services, and support in biology, chemistry, and pharmacokinetics. Supported by a workforce of 3,135 employees, including 2,353 scientific staff with 302 Ph.D.s and 1,475 master’s degrees, Sai Life Sciences drives innovation with a globally positioned business development team of 16 professionals.
Strengths
- Integrated Platform: Offers end-to-end services from drug discovery to manufacturing.
- Diverse Portfolio: Capable of managing molecules across early-stage and commercial phases.
- Advanced Capabilities: Leverages cutting-edge technologies in biology, chemistry, and DMPK.
Risk factors
- Customer Dependency: A significant portion of revenue comes from biotechnology and pharmaceutical clients, making the company vulnerable to industry-specific challenges, such as delays or failures in drug development and manufacturing.
- Compliance Risks: Failure to meet customer standards during audits or inspections could damage reputation and potentially result in termination of contracts.
- Market Uncertainties: Changes in customer demand, regulatory landscape, or industry trends may adversely affect business performance and growth prospects.
Promoters
Kanumuri Ranga Raju
Krishnam Raju Kanumuri
Kanumuri Mytrey
Sai Quest Syn Private Limited
Sunflower Partners
Lily Partners
Marigold Partners
Tulip Partners
Registrar & documents
Lead manager
Kotak Mahindra Capital Company, IIFL Capital Services Limited, Jefferies India Private Limited, Morgan Stanley India Company Private Limited
Registrar & contacts
Kfin Technologies Limited
[email protected]Official registrar portal ↗IPO allotment status guide →Registered office
Plot No. DS-7, IKP Knowledge Park, Turkapally Village, Shameerpet Mandal, Malkajgiri District, Hyderabad-500078
+9140 6815 6000
[email protected]Company website ↗Understanding SAILIFE IPO data
Compare the price band and required investment with the company profile, financial results and offer documents. Subscription figures show reported demand by category; they do not establish the value of the business. GMP is an unofficial indication and can change before listing.